Global Health Look at Atopic Dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects standardized clinical data from routine care across multiple centers to understand treatment patterns, disease severity, healthcare access, and quality of life in people with atopic dermatitis. It uses both retrospective and prospective data from January 2020 onward to identify disparities across health systems. The study is hosted by the University of Zurich and involves collaboration with its hospital and related institutions. Participation relies on informed consent and accurate diagnosis in the records. No specific interventions are implemented in this design.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed General Consent Form, or equivalent document
* Confirmed diagnosis of Atopic Dermatitis

Exclusion Criteria:

* Inability to provide informed consent.
* Datasets with ambiguous or unclear diagnosis.

Where it's running

• University of Zurich
  Zurich, Switzerland Recruiting

Study contacts

• Principal investigator: Julia-Tatjana Maul, Prof. Dr. med. — University of Zurich
• Study coordinator: Julia-Tatjana Maul, Prof. Dr. med.
• Email: julia-tatjana.maul@usz.ch
• Phone: +41 76 441 51 09

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a new hydrogel for treating mild to moderate eczema

  This study is testing a new hydrogel called zabalafin to see if it helps people with mild to moderate eczema feel better compared to a placebo.

  Recruiting at 12 sites Phase 2 Alphyn Biologics · Brookvale, New South Wales and 11 other locations · NCT06855745

• Herbal ointment for treating atopic dermatitis

  This study is testing a herbal ointment made from a plant to see if it can help people with atopic dermatitis feel better.

  Recruiting Phase 2/3 En Chu Kong Hospital · New Taipei City · NCT06850311

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy

  This study tests whether nemolizumab changes skin structure in adults with moderate-to-severe atopic dermatitis using a noninvasive imaging method.

  Recruiting Hôpitaux Drôme Nord · Romans-sur-Isère, Drôme · NCT07730788

• LT-002-158 tablets for moderate-to-severe atopic dermatitis in adults

  This study tests LT-002-158 vs placebo to see if it helps adults with moderate-to-severe atopic dermatitis.

  Recruiting Phase 2 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Hangzhou, Zhejiang · NCT07895615

• PRA-216 for moderate to severe atopic dermatitis: safety and how it works in the body

  This study tests PRA-216 versus placebo to see if it is safe and helps people with moderate to severe atopic dermatitis.

  Recruiting at 6 sites Phase 2 Prana Therapies Inc · Botany, New South Wales and 8 other locations · NCT07810777

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.